Genmab Says Phase 3 EPCORE FL-1 Clinical Trial Met Dual Primary Endpoints In Patients With R/R FL
RefinitivThời gian đọc: dưới 1 phút
Genmab A/S GMAB:
GENMAB ANNOUNCES PHASE 3 EPCORE® FL-1 CLINICAL TRIAL MET DUAL PRIMARY ENDPOINTS IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)
GENMAB - FDA HAS ACCEPTED FOR PRIORITY REVIEW NEW SBLA FOR EPCORITAMAB PLUS R(2), WITH ACTION DATE OF NOVEMBER 30
Đăng nhập hoặc tạo tài khoản miễn phí trọn đời để đọc tin tức này